Integrity Alliance LLC. Acquires 3,186 Shares of Cencora, Inc. $COR

Key Points

• Integrity Alliance LLC. increased its stake in Cencora, Inc. by 54.3%, acquiring an additional 3,186 shares to bring its total holdings to 9,053 shares, valued at $2,518,000.
• CEO Robert P. Mauch and Chairman Steven H. Collis sold shares of Cencora stock, reducing their ownership by 10.50% and 4.49% respectively, while insiders collectively own 10.80% of the company.
• Cencora reported a quarterly EPS of $4.00, exceeding estimates, and has announced a dividend of $0.55 per share, reflecting a 0.7% dividend yield.

Integrity Alliance LLC. raised its holdings in Cencora, Inc. (NYSE:COR - Free Report) by 54.3% in the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 9,053 shares of the company's stock after purchasing an additional 3,186 shares during the period. Integrity Alliance LLC.'s holdings in Cencora were worth $2,518,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently made changes to their positions in COR. Price T Rowe Associates Inc. MD boosted its stake in shares of Cencora by 8.9% in the first quarter. Price T Rowe Associates Inc. MD now owns 9,647,310 shares of the company's stock valued at $2,682,821,000 after buying an additional 787,858 shares during the period. Wellington Management Group LLP increased its stake in Cencora by 7.2% during the 1st quarter. Wellington Management Group LLP now owns 5,421,262 shares of the company's stock worth $1,507,599,000 after acquiring an additional 363,402 shares during the period. Boston Partners lifted its position in shares of Cencora by 8.1% during the 1st quarter. Boston Partners now owns 5,411,193 shares of the company's stock valued at $1,505,984,000 after acquiring an additional 404,093 shares during the period. Invesco Ltd. lifted its position in shares of Cencora by 42.1% during the 1st quarter. Invesco Ltd. now owns 4,607,964 shares of the company's stock valued at $1,281,429,000 after acquiring an additional 1,364,433 shares during the period. Finally, Goldman Sachs Group Inc. grew its holdings in shares of Cencora by 9.9% during the 1st quarter. Goldman Sachs Group Inc. now owns 1,711,281 shares of the company's stock worth $475,890,000 after purchasing an additional 154,311 shares in the last quarter. Institutional investors and hedge funds own 97.52% of the company's stock.

Insider Buying and Selling at Cencora

In related news, CEO Robert P. Mauch sold 4,968 shares of the business's stock in a transaction on Friday, July 18th. The stock was sold at an average price of $294.11, for a total transaction of $1,461,138.48. Following the sale, the chief executive officer owned 42,351 shares in the company, valued at $12,455,852.61. The trade was a 10.50% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Chairman Steven H. Collis sold 14,578 shares of the stock in a transaction dated Tuesday, July 22nd. The shares were sold at an average price of $292.67, for a total value of $4,266,543.26. Following the completion of the transaction, the chairman owned 309,913 shares of the company's stock, valued at $90,702,237.71. This represents a 4.49% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 34,125 shares of company stock worth $9,993,789. 10.80% of the stock is currently owned by company insiders.

Cencora Stock Down 0.8%

Shares of NYSE COR opened at $296.38 on Thursday. The company has a market cap of $57.46 billion, a price-to-earnings ratio of 30.49, a PEG ratio of 1.42 and a beta of 0.62. The company has a current ratio of 0.90, a quick ratio of 0.53 and a debt-to-equity ratio of 3.64. Cencora, Inc. has a 12 month low of $218.65 and a 12 month high of $309.35. The stock has a 50-day moving average price of $292.98 and a two-hundred day moving average price of $284.73.

Cencora (NYSE:COR - Get Free Report) last announced its quarterly earnings results on Wednesday, August 6th. The company reported $4.00 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.79 by $0.21. The company had revenue of $80.66 billion for the quarter, compared to analyst estimates of $80.34 billion. Cencora had a net margin of 0.60% and a return on equity of 267.36%. The firm's revenue was up 8.7% on a year-over-year basis. During the same period in the previous year, the firm posted $3.34 EPS. As a group, analysts forecast that Cencora, Inc. will post 15.37 earnings per share for the current fiscal year.

Cencora Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Wednesday, September 3rd. Investors of record on Friday, August 15th were issued a dividend of $0.55 per share. The ex-dividend date of this dividend was Friday, August 15th. This represents a $2.20 annualized dividend and a dividend yield of 0.7%. Cencora's dividend payout ratio (DPR) is 22.63%.

Analyst Upgrades and Downgrades

COR has been the subject of several recent analyst reports. Jefferies Financial Group upped their price objective on shares of Cencora from $275.00 to $300.00 and gave the stock a "hold" rating in a research report on Monday, June 30th. Morgan Stanley set a $330.00 target price on shares of Cencora and gave the company an "equal weight" rating in a research report on Wednesday, July 16th. Finally, Wells Fargo & Company increased their price target on shares of Cencora from $337.00 to $354.00 and gave the stock an "overweight" rating in a research report on Wednesday, August 13th. Nine research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company's stock. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average price target of $311.25.

Cencora Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.